Support
: 888-992-3836
|
Newswire
|
Home
|
Log in
Boards
Stocks
Commodities
Forex
Cryptocurrency
The Lounge
Hot!
Breakout Boards
Follow Feed
iHub My Stocks Activity
Ticker Buzz Cloud
Most Read
Most Posted
Most Followed Members
Recent News
Active Boards
Site Stats
New Boards
Cannabis Stocks
Top PlusOneCoin Posters
Tools
Data Tools >
Charts
Trader Alerts
Trades
Portfolio
Top Lists
Price & News Alerts
Commodities
Markets in 3D
NewsWire
More Tools >
Newsletters
My Image Gallery
Advanced Search
Videos
All News
Stock Screener
News Filter
Live Charts
Live News
Live Desktop
Forex Prices
Commodities
ETF Center
Educational Channel
Personal Finance Q&A
Follow Feed
Crypto
Cryptocurrency
PlusOneCoin Learn
Streamer
Level 2
Home
>
Boards
>
US Listed
>
Biotechs
>
Icon Plc (ICLR)
Add ICLR Price Alert
Hide Sticky
Hide Intro
Moderator:
Search This Board:
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003+
Last Post:
2/12/2017 3:15:42 PM
-
Followers:
1
- Board type:
Free
- Posts Today:
0
ICON
A Symbol Of Excellence
(We are a European (Irish) company and therefore use British English on our website, hence the s usage, and British spelling.
)
ICON is a Global Contract Research Organization (CRO). We specialise in the strategic development, management and analysis of programs that support Clinical Development; from compound selection to Phase I-IV clinical studies.
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies.
n a highly fragmented industry, we are one of a small group of organizations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis.
ICON Announces the Commencement of Direct Trading on NASDAQ
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, commenced direct trading of ICON ordinary shares on NASDAQ (CUSIP Number G4705A 100) yesterday, 4th February 2013. This follows ICON's withdrawal from the Irish Stock Exchange on the 30th January 2013 and the termination of the ADR programme in accordance with the resolutions approved by the shareholders at the Extraordinary General Meeting of the Company on 17th December 2012.
The information contained in this release is as of 5th February 2013. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON's Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 82 locations in 40 countries and has approximately 9,430 employees. Further information is available at
http://www.iconplc.com.
ICON/ICLR-F
ICON
Investor Relations
1-888-381-7923
or
Brendan Brennan
Chief Financial Officer
+ 353 -1-291-2000
or
Sam Farthing
VP Investor Relations
+ 353 -1-291-2000
http://investor.iconplc.com/
ICLR
Current Price
Volume:
Bid
Ask
Day's Range
ICLR Detailed Quote
1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y
ICLR News: ICON Announces Agreement with Intel Allowing Integration of the Intel® Pharma Analytics Platform for Clinical Trials
04/17/2018 07:28:00 AM
ICLR News: ICON Announces Launch of Government and Public Health Solutions to Support Global Public Health
04/03/2018 08:00:00 AM
ICLR News: Annual and Transition Report (foreign Private Issuer) (20-f)
02/28/2018 05:25:51 PM
ICLR News: Report of Foreign Issuer (6-k)
02/15/2018 06:46:21 AM
ICLR News: ICON Reports Fourth Quarter and Full Year 2017 Results
02/15/2018 06:00:00 AM
Post New Msg
Follow Board
My Stocks (0)
Hide Intro
View Posters
ICLR Poststream
Bans (0)
Hide Quote
Filter Disabled
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
Post
Subject
#17
0
ICON is scheduled to report earnings on Thursday
ValueInvestor15
02/12/17 03:15:42 PM
#16
0
ICLR bullish 76.12
stocktrademan
08/10/16 10:17:16 AM
#15
0
SEC suspension cancelled.
IPO$
10/22/14 12:48:10 PM
#14
0
ICLR: SEC Admin Proceeding still active:
Renee
10/22/14 11:23:36 AM
#13
0
ICLR SEC Suspension cancelled.
Renee
10/22/14 10:06:16 AM
#12
0
ICLR: SEC Suspension:
Renee
10/22/14 09:33:37 AM
#11
0
$ICLR DD Notes ~ http://www.ddnotesmaker.com/ICLR
stocktrademan
09/10/14 01:01:50 PM
#10
0
News Story
johnsyn
03/27/14 07:37:54 PM
#9
0
http://seekingalpha.com/article/1575362-icon-plc-ordinary-shares-iclr-management
johnsyn
07/27/13 07:35:59 AM
#8
0
http://seekingalpha.com/article/1372991-icon-public-limited-management-discusses
johnsyn
04/25/13 08:06:55 PM
#7
0
6:41 AM ICON plc (ICLR): Q1 EPS of
johnsyn
04/25/13 08:16:41 AM
#6
0
http://www.marketintelligencecenter.com/articles/269311 ICON Plc (ICLR) Market Cap: $1.96 billion
johnsyn
04/02/13 01:22:23 PM
#5
0
ICON Announces Appointment of Professor William Hall to
johnsyn
02/22/13 09:41:05 AM
#4
0
Jeffries raises P/T to $33.50, Raymond James raises
johnsyn
02/20/13 03:11:18 PM
#3
0
ICON To Acquire Clinical Trial Services Division of
johnsyn
02/19/13 05:29:42 PM
#2
0
Cross Country Healthcare Completes Sale of Its Clinical
johnsyn
02/19/13 05:28:39 PM
#1
0
ICON Reports Fourth Quarter 2012 Revenue of $300
johnsyn
02/19/13 05:27:39 PM
Post
Subject
Post New Msg
Follow Board
My Stocks (0)
Hide Intro
View Posters
ICLR Poststream
Bans (0)
Hide Quote
Filter Disabled
Balance Available:
0
© 2018 InvestorsHub.com, Inc.